Journey Medical (DERM) Income towards Parent Company (2020 - 2026)

Journey Medical has reported Income towards Parent Company for 7 years, with the latest figure at -$2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 45.25% year-over-year to -$2.2 million; the trailing twelve-month figure through Mar 2026 stood at -$9.6 million (down 16.33% YoY), and the FY2025 full-year result was -$11.4 million, up 22.09% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$2.2 million, down from -$1.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was $16.8 million in Q3 2023, with the low at -$10.6 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$3.6 million across 5 years, with a median of -$3.4 million in 2024.
• The largest YoY upside for Income towards Parent Company was 266.56% in 2023 against a maximum downside of 635.56% in 2023.
• Journey Medical's Income towards Parent Company stood at -$10.6 million in 2022, then jumped by 79.86% to -$2.1 million in 2023, then jumped by 173.82% to $1.6 million in 2024, then tumbled by 178.82% to -$1.2 million in 2025, then tumbled by 78.83% to -$2.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$2.2 million (Q1 2026), -$1.2 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.